Search

Batch SPM systems do not meet the current clean specification/requirements below 28nm. Single wafer SPM systems use a high volume of chemistry which runs to drain, while meeting the cleaning specifications below 28nm. The work in this paper describe the use of a batch SPM system and a single wafer clean in an integrated system, Ultra-C Tahoe which results in meeting the technical specification and using less that 80% of the SPM chemistry used in single wafer systems. The data collected shows this new system meet the specifications, whilst saving more than 80%of SPM chemistry.

Additional file 2: Supplementary Fig. 1. The classification plot of samples from three cell lines based on all the DEGs. Cells were treated with (3, 12, 24 h.p.i.) or without (normal group) ZIKV infection; Supplementary Fig. 2. The expression heatmap of 33 common DEGs among JEG-3, U-251 MG, and HK-2 cells; Supplementary Fig 3. The enriched GO BPs of DEGs from 3 cell lines, including (a) JEG-3, (b) U-251 MG, (c) HK-2 cells. Supplementary Table 1. DEGs in JEG-3 cells of 24h; Supplementary Table 2. DEGs in U-251 MG cells of 24h; Supplementary Table 3. DEGs in HK-2 cells of 24h; Supplementary Table 4. 33 common DEGs and functions in 3 cell lines; Supplementary Table 5. The GO-BP enrichment of DEGs in JEG-3 cells of 24h; Supplementary Table 6. The GO-BP enrichment of up-regulated DEGs in JEG-3 cells of 24h; Supplementary Table 7. The GO-BP enrichment of down-regulated DEGs in JEG-3 cells of 24h; Supplementary Table 8. The GO-BP enrichment of DEGs in U-251 MG cells of 24h; Supplementary Table 9. The GO-BP enrichment of up-regulated DEGs in U-251 MG cells of 24h; Supplementary Table 10. The GO-BP enrichment of down-regulated DEGs in U-251 MG cells of 24h; Supplementary Table 11. The GO-BP enrichment of DEGs in HK-2 cells of 24h; Supplementary Table 12. The GO-BP enrichment of up-regulated DEGs in HK-2 cells of 24h; Supplementary Table 13. The GO-BP enrichment of down-regulated DEGs in HK-2 cells of 24h; Supplementary Table 14. The pathway enrichment of DEGs in JEG-3 cells of 24h; Supplementary Table 15. The pathway enrichment of DEGs in U-251 MG cells of 24h; Supplementary Table 16. The pathway enrichment of DEGs in HK-2 cells of 24h; Supplementary Table 17. DEGs in JEG-3 cells of 3h; Supplementary Table 18. DEGs in JEG-3 cells of 12h; Supplementary Table 19. The GO-BP enrichment of DEGs in JEG-3 cells of 3h; Supplementary Table 20. The GO-BP enrichmentin of up-regulated DEGs in JEG-3 cells of 3h; Supplementary Table 21. The pathway enrichment of DEGs in JEG-3 cells of 3h.

Background: Cardiovascular disease is the primary cause of human mortality every year in several countries worldwide. It is a significant concern from a public health perspective as well. There are several therapies available in the market to treat cardiovascular diseases. Statins are considered the best therapy among the other drugs due to their multifunctional effects, such as antioxidant and anti-inflammation. Objective: Statins are the best HMG-CoA reductase inhibitor to date, after considering the several trial reports like PROVE-IT, MEGA, LIPID CARE, ALLHAT-LLT, PROSPER to demonstrate the statin effectivity. Methods: The different databases were studied for a comparison of statin treatment group versus control trial group. Multivariate regression analysis and other meta-analyses were performed. Statin efficacy with the other drugs and some studies were done to compare the effectiveness within different statin groups. Results and Discussions: The findings showed a 10% mortality reduction among patients in the statin groups (Risk Ratio 0.89: 95% CI, 0.87–0.95, I2 value 16%, P value ≤ 0.0001,). About 1.1% mortality reduction occurred with the 10% low density lipoprotein change, (P value 0.003, 95% CI,0.29–1.18), a 20% reduction in cardiovascular mortality was documented in the statin treated patients than in the control patients (RR 0.80, 95% CI value 0.73–0.88, I2 value 27%, P value < 0.0001). Myocardial risk reduction was about 18% (RR 0.83, P-value < 0.0001, I2 = 21%, 95% CI 0.76–0.90). Despite minimum adverse effects, there was a significantly increased rate of diabetes in the statin group (OR 1.07, P-value=0.0008, 95% CI 1.03–1.17, I2 value 16%). Conclusion: It has been found that statin is very safe to use in cardiovascular disease treatment, and found effective in limiting the LDL-c levels compared to the other kind of drugs such as Benazepril, Captopril, Enalapril, Iprosartan, Losartan, Olmesarta. [Ethiop. J. Health Dev. 2021: 35(4):297-308] Keywords: Statin, Cardiovascular disease, HMG-CoA reductase, Low-density Lipoprotein, efficacy, cholesterol, Randomized trial, Control trail.